MedTrace Logo

Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men

NCT02436486 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2015-09-22

No results posted yet for this study

Summary

To evaluate the effect of idalopirdine (120 and 360 mg) on cardiac repolarisation in healthy men.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Placebo

Capsules, orally, single dose

DRUG

ldalopirdine 120 mg

Two 60 mg encapsulated film-coated tablets, orally, single dose

DRUG

Idalopirdine 360 mg

Four 90 mg encapsulated film-coated tablets, orally, single dose

DRUG

Moxifloxacin 400 mg

Encapsulated tablets, orally, single dose

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02436486 on ClinicalTrials.gov